Calamos Advisors
CORT icon

Calamos Advisors’s Corcept Therapeutics CORT Stock Holding History

Calamos Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-25,882
Closed -$2.15M – 943
2025
Q3 		$2.15M Sell
25,882
-43,325
-63% -$3.14M 0.01% 617
2025
Q2 		$5.08M Buy
69,207
+5,093
+8% +$369K 0.02% 549
2025
Q1 		$7.32M Buy
64,114
+24,788
+63% +$1.51M 0.03% 452
2024
Q4 		$1.98M Sell
39,326
-4,908
-11% -$257K 0.01% 608
2024
Q3 		$2.05M Buy
44,234
+32,755
+285% +$1.16M 0.01% 614
2024
Q2 		$373K Buy
+11,479
New +$314K ﹤0.01% 726

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Calamos Advisors's CORT Position: Q4 2025 in Review

Calamos Advisors sold out of Corcept Therapeutics (CORT) in Q4 2025, closing a stake of 25,882 shares — an estimated $2.15M sold.

Calamos Advisors first reported a position in CORT in Q2 2024 and held it in 6 quarters. The position peaked at $7.32M in Q1 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.

  • Calamos Advisors reported no remaining Corcept Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Calamos Advisors sold 25,882 Corcept Therapeutics shares in Q4 2025, an estimated $2.15M.
  • Calamos Advisors first reported a position in Corcept Therapeutics in Q2 2024 and held it in 6 quarters.
  • Calamos Advisors's Corcept Therapeutics position peaked at $7.32M in Q1 2025.
  • 389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.

Based on Calamos Advisors's 13F filing for Q4 2025, filed 29 Jan 2026.